Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ALMR
Alamar Biosciences
$28.68
-6.0%
$30.31
$18.84
▼
$39.61
$2.12BN/A733,057 shs326,540 shs
Azenta, Inc. stock logo
AZTA
Azenta
$47.08
-3.3%
$37.84
$15.93
▼
$50.06
$2.13B1.471.02 million shs1.37 million shs
CryoPort, Inc. stock logo
CYRX
CryoPort
$19.55
-3.1%
$17.78
$7.61
▼
$21.78
$1.02B1.891.25 million shs676,646 shs
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
$7.19
-2.6%
$7.42
$2.80
▼
$9.42
$1.92B0.612.18 million shs2.62 million shs
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ALMR
Alamar Biosciences
-6.00%-9.70%+1.85%-16.24%+2,867,999,900.00%
Azenta, Inc. stock logo
AZTA
Azenta
-3.30%+7.35%+31.78%+25.89%+56.79%
CryoPort, Inc. stock logo
CYRX
CryoPort
-3.07%-2.74%+12.10%+14.13%+131.09%
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
-2.57%-6.38%-0.14%-16.78%+105.43%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ALMR
Alamar Biosciences
$28.68
-6.0%
$30.31
$18.84
▼
$39.61
$2.12BN/A733,057 shs326,540 shs
Azenta, Inc. stock logo
AZTA
Azenta
$47.08
-3.3%
$37.84
$15.93
▼
$50.06
$2.13B1.471.02 million shs1.37 million shs
CryoPort, Inc. stock logo
CYRX
CryoPort
$19.55
-3.1%
$17.78
$7.61
▼
$21.78
$1.02B1.891.25 million shs676,646 shs
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
$7.19
-2.6%
$7.42
$2.80
▼
$9.42
$1.92B0.612.18 million shs2.62 million shs
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ALMR
Alamar Biosciences
-6.00%-9.70%+1.85%-16.24%+2,867,999,900.00%
Azenta, Inc. stock logo
AZTA
Azenta
-3.30%+7.35%+31.78%+25.89%+56.79%
CryoPort, Inc. stock logo
CYRX
CryoPort
-3.07%-2.74%+12.10%+14.13%+131.09%
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
-2.57%-6.38%-0.14%-16.78%+105.43%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ALMR
Alamar Biosciences
2.57
Moderate Buy$33.0015.06% Upside
Azenta, Inc. stock logo
AZTA
Azenta
2.43
Hold$47.601.10% Upside
CryoPort, Inc. stock logo
CYRX
CryoPort
2.78
Moderate Buy$21.6910.93% Upside
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
2.67
Moderate Buy$8.1012.66% Upside

Current Analyst Ratings Breakdown

Latest CYRX, ALMR, AZTA, and MRVI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/12/2026
Azenta, Inc. stock logo
AZTA
Azenta
Initiated CoverageHold
11/12/2026
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
UpgradeSector Weight ➝ Overweight$11.00
11/11/2026
Azenta, Inc. stock logo
AZTA
Azenta
Boost Price TargetBuy$37.00 ➝ $57.00
11/11/2026
Azenta, Inc. stock logo
AZTA
Azenta
Boost Price TargetBuy$44.00 ➝ $52.00
11/6/2026
CryoPort, Inc. stock logo
CYRX
CryoPort
Boost Price TargetBuy$19.00 ➝ $28.00
11/6/2026
CryoPort, Inc. stock logo
CYRX
CryoPort
Boost Price TargetOverweight$17.00 ➝ $20.00
11/4/2026
ALMR
Alamar Biosciences
UpgradeSell (D+) ➝ Hold (C-)
11/4/2026
ALMR
Alamar Biosciences
Boost Price TargetBuy$34.00 ➝ $36.00
10/23/2026
ALMR
Alamar Biosciences
DowngradeHold (C-) ➝ Sell (D+)
10/13/2026
CryoPort, Inc. stock logo
CYRX
CryoPort
Set Price Target$26.00
10/13/2026
CryoPort, Inc. stock logo
CYRX
CryoPort
UpgradeBuy
(Data available from 11/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ALMR
Alamar Biosciences
$74.21M26.85N/AN/A$4.37 per share6.56
Azenta, Inc. stock logo
AZTA
Azenta
$621.70M3.32$4.99 per share9.44$31.89 per share1.48
CryoPort, Inc. stock logo
CYRX
CryoPort
$176.18M5.63N/AN/A$8.58 per share2.28
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
$185.74M10.06$0.41 per share17.63$1.31 per share5.49
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ALMR
Alamar Biosciences
-$29.82M-$2.15N/AN/AN/A-48.22%-78.71%-20.08%N/A
Azenta, Inc. stock logo
AZTA
Azenta
-$166.99M-$3.62N/A56.05N/A-26.86%1.41%1.15%2/3/2027 (Estimated)
CryoPort, Inc. stock logo
CYRX
CryoPort
$78.30M-$0.97N/AN/AN/A-21.46%-8.28%-4.88%N/A
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
-$130.77M-$0.43N/AN/AN/A-30.83%-12.44%-6.66%N/A

Latest CYRX, ALMR, AZTA, and MRVI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/10/2026Q4 2026
Azenta, Inc. stock logo
AZTA
Azenta
$0.1110$0.28+$0.1690$0.16$160.16 million$167.09 million
11/5/2026Q3 2026
CryoPort, Inc. stock logo
CYRX
CryoPort
-$0.1769-$0.25-$0.0732-$0.25$48.66 million$50.22 million
11/4/2026Q3 2026
ALMR
Alamar Biosciences
-$0.22-$0.19+$0.03-$0.19N/A$33.55 million
11/4/2026Q3 2026
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
-$0.0563-$0.03+$0.0263-$0.09$43.56 million$45.85 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
ALMR
Alamar Biosciences
N/AN/AN/AN/AN/A
Azenta, Inc. stock logo
AZTA
Azenta
N/AN/A-100.00%N/AN/A
CryoPort, Inc. stock logo
CYRX
CryoPort
N/AN/AN/AN/AN/A
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ALMR
Alamar Biosciences
N/A
9.49
7.87
Azenta, Inc. stock logo
AZTA
Azenta
N/A
2.68
2.34
CryoPort, Inc. stock logo
CYRX
CryoPort
N/A
2.04
1.94
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
0.51
4.66
3.35

Institutional Ownership

CompanyInstitutional Ownership
ALMR
Alamar Biosciences
N/A
Azenta, Inc. stock logo
AZTA
Azenta
99.08%
CryoPort, Inc. stock logo
CYRX
CryoPort
92.90%
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
50.25%

Insider Ownership

CompanyInsider Ownership
ALMR
Alamar Biosciences
N/A
Azenta, Inc. stock logo
AZTA
Azenta
10.90%
CryoPort, Inc. stock logo
CYRX
CryoPort
9.50%
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
2.49%
CompanyEmployeesShares OutstandingFree FloatOptionable
ALMR
Alamar Biosciences
22269.48 millionN/AN/A
Azenta, Inc. stock logo
AZTA
Azenta
3,00043.81 million39.03 millionOptionable
CryoPort, Inc. stock logo
CYRX
CryoPort
73850.70 million45.88 millionOptionable
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
410259.94 million253.47 millionOptionable

Recent News About These Companies

Q1 Earnings Forecast for MRVI Issued By KeyCorp
Brokers Offer Predictions for MRVI Q1 Earnings
Q3 Earnings Forecast for MRVI Issued By KeyCorp
Maravai LifeSciences (NASDAQ:MRVI) Raised to Overweight at KeyCorp
Maravai LifeSciences (MRVI) Q3 2026 Earnings Call Transcript

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alamar Biosciences NASDAQ:ALMR

$28.68 -1.83 (-6.00%)
As of 11/19/2026 04:00 PM Eastern

Our mission is to power precision proteomics to enable the earliest detection of disease. We are a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Our proprietary NULISA technology was purpose-built to address the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation. We refer to this combination of features as “Precision Proteomics,” and believe it fills a critical gap in the field of advanced proteomics, enabling researchers to establish the relationship between incremental changes in multiplexed protein biomarkers and the clinically meaningful differences in health, disease and drug therapy. Our integrated platform consists of proprietary instruments, consumables and analytical software that is designed to provide scientists with an end-to-end solution to precisely and consistently measure from one to hundreds of low-abundance and difficult-to-detect biomarkers across the continuum of discovery, translational research and ultimately diagnostics. We commercially launched our proprietary instrument, the ARGO High Throughput (“HT”) System in January 2024 and have already experienced rapid adoption, with more than 300 customers across 25 countries and a cumulative installed base of over 100 instruments with an average annual pull-through greater than $400,000 per instrument for the year ended December 31, 2025. The robust performance of our platform is further evidenced in over 100 scientific publications since our commercial launch. Our customers include top global research and academic institutions, biopharmaceutical companies, contract research organizations and service labs. All ten of the top ten biopharma companies by 2024 revenue are customers of Alamar. We are also developing a second proprietary instrument as part of our IVD platform, called the ARGO HT/DX instrument, for which we intend to provide a submission to the FDA for marketing authorization in 2027. We have established multiple multi-million dollar collaborations with renowned research foundations to help support the development of our ARGO HT/DX instrument and the discovery of biomarkers in neurodegenerative disease. Proteins are essential for all life functions and the fundamental molecules behind healthy cellular operations and the causal mechanisms of disease, as illustrated by the fact that a large majority of effective drugs have proteins as targets. Proteomic analysis has great potential to identify “biomarkers” of health, to characterize disturbances in disease, to discover new drug targets, to assess risks and to measure the impact of interventions such as drugs and lifestyle changes. However, the complexity of disease and biology requires analysis of multiple proteins and pathways at once. As a result of this complexity, much of the human proteome has remained unmeasurable or unquantifiable by other proteomic technologies, and true Precision Proteomics has not been possible. Our proprietary and patented NULISA technology addresses these critical limitations, and we believe it is currently the only platform that enables Precision Proteomics. The chemistry underpinning our technology employs a unique sequential purification of immunocomplexes to suppress background noise and enable the detection of low-abundance protein targets in biofluids across large and diverse populations. Our platform is a fully integrated and fully automated proteomic analysis solution and provides scientists with an end-to-end solution to precisely and consistently measure from one to over one hundred low-abundance and difficult-to-detect biomarkers across the continuum of discovery, translational research, and ultimately, diagnostics. Scientists value our platform because it offers an accessible, easy-to-use and reliable ultra-high sensitivity and multiplexed biomarker analysis of large cohorts of samples. Our current instrument, the ARGO HT System, is designed to fully automate high-sensitivity and high-plex proteomics analysis and is currently available for research use only (“RUO”) applications. It was built to execute our NULISA chemistry in a simple and reproducible workflow for broad biomarker profiling, validation and potential translation into future clinical use. The ARGO HT System facilitates the seamless analysis of large cohorts and clinical research with minimal handling, rapid turnaround times and high data quality. Our initial assay menu focuses on neurology and immunology. We develop a significant portion of our assay panels in close partnership with our customers, who are experts in identifying important protein biomarkers in their respective fields. Our flagship multiplex assay, the CNS Disease Panel 120, provides broad coverage of neurodegeneration pathways. Additionally, our single-plex BD-pTau217 assay can distinctly measure brain-derived-pTau217, which is present in low abundance in blood and is critical for research involving biomarkers for early diagnosis of Alzheimer’s disease. Our assay enables BD-pTau217 quantitation using a small blood sample, offering a noninvasive, economical and convenient alternative to cerebrospinal fluid sample tests or PET scans. We also develop kits for customers to create their own assays, enabling our technology to meet the needs of customers operating in their disease areas of interest. The flexibility of our platform is designed to enable researchers to seamlessly transition from high-plex discovery panels to the development of low-plex diagnostics assays. As a result, our strategy is to continue driving adoption in the targeted discovery and translational markets and subsequently establish a foundation for clinical diagnostics through internal innovation and external collaborations. Ultimately, our platform is designed to support the entire customer journey from discovery to diagnostics, unlocking the full value of precision medicine and early disease detection. We were founded in May 2018 as a Delaware corporation. Our principal executive offices are located in Fremont, California.

Azenta stock logo

Azenta NASDAQ:AZTA

$47.08 -1.61 (-3.30%)
Closing price 11/19/2026 03:59 PM Eastern
Extended Trading
$46.52 -0.56 (-1.19%)
As of 11/19/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold storage solutions, consumables and instruments, controlled rate thawing devices, and temperature-controlled storage and transportation solutions. This segment also provides sample management solutions, such as consumable vials and tubes, polymerase chain reaction, plates, instruments for supporting workflows, and informatics. The Life Sciences Services segment provides genomic services, that includes gene sequencing and gene synthesis services; and sample repository solutions, such as on-site and off-site sample storage, cold chain logistics, sample transport and collection relocation, bio-processing solutions, disaster recovery and business continuity, and biospecimen procurement services, as well as project management and consulting services for genomic analysis and the management and care of biological samples used in pharmaceutical, biotech, healthcare, clinical, and academic research, and development sectors. It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.

CryoPort stock logo

CryoPort NASDAQ:CYRX

$19.55 -0.62 (-3.07%)
Closing price 11/19/2026 04:00 PM Eastern
Extended Trading
$19.56 +0.00 (+0.03%)
As of 11/19/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

Maravai LifeSciences stock logo

Maravai LifeSciences NASDAQ:MRVI

$7.19 -0.19 (-2.57%)
Closing price 11/19/2026 04:00 PM Eastern
Extended Trading
$7.12 -0.08 (-1.04%)
As of 11/19/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.